tbuckley/cabot-search huggingface dataset:
Current Pediatric Therapy.
Journal: Annals of Internal Medicine (1977)

Section 1 -- Nutrition Section 2 -- Fluid and Electrolytes Section 3 -- Infectious Diseases Section 4 -- Special Problems in the Infant and Neonate Section 5 -- Mental Development and Behavioral Disorders Section 6 -- Nervous System Section 7 -- Respiratory Tract Section 8 -- Cardiovascular System Section 9 -- Digestive Tract Section 10 -- Hematology Section 11 -- Endocrine System Section 12 -- Metabolic Disorders Section 13 -- Connective Tissue Section 14 -- Nephrology and Genitourinary Tract Section 15 -- Skeletal System Section 16 -- Muscles Section 17 -- Skin Section 18 -- The Eye Section 19 -- Ear, Nose and Throat Section 20 -- Allergy Section 21 -- Immunology Section 22 -- Cancer Section 23 -- Accidents and Emergencies Section 24 -- Special Problems in the Adolescent Section 25 -- Dental Problems
Clonal Evolution Paths Significantly Impact the Outcome of Myeloma
Authors: Xiaoqi Qin, Gang An, Lin-ping Hu, Yu Qin, Yan Xu, Xiaoyan Feng, Meirong Zang, Shuhui Deng, Weiwei Sui, Shuhua Yi, Zengjun Li, Lin-hua Yang, Tao Cheng, Jianxiang Wang, Lugui Qiu
Journal: Blood (2015)
The Equal Activity of Azacytidine in 4 Risk Groups of IPSS in MDS.
Authors: Soo-Mee Bang, In-Ho Kim, Seonyang Park, Byoung Kook Kim, Je-Hwan Lee, Jung-Hee Lee, Kyoo-Hyung Lee, Yeo-Kyeoung Kim, Jae-Sook Ahn, Hyeoung Joon Kim, Sung-Hwa Bae, Hun-Mo Ryoo, Mark Lee, Ho-Jin Shin, Yoo-Hong Min, Jae Hoon Lee, Yeung-Chul Mun, Jong-Ho Won, Doyeun Oh
Journal: Blood (2007)
The Function of Toll-Like Receptor 4 Expressions on Human Platelet in Platelet Activation
Authors: Liping Ma, Da-Nian Nie, Xiu-Ju Wang, Shuang-Fen Xie, Yi-Qing Li, Yu-Dan Wu, Zhi-Xin Pei, Cheng Zhang, Song-Mei Yin
Journal: Blood (2008)
Human Mesenchymal Stem Cells Inhibit In Vitro Antibody Production Against Alloantigens.
Authors: Patrizia Comoli, Rita Maccario, Maria Antonietta Avanzini, Fabrizio Ginevri, Antonia Moretta, Marina Podestà, Massimo Marconi, Angela Cometa, Maria Ester Bernardo, Francesco Frassoni, Franco Locatelli
Journal: Blood (2005)
Synergistic Induction of Cell Death in Hodgkin Lymphoma Cells By the Novel PI3K Inhibitor RP6530 Combined with Brentuximab Vedotin (SGN-35) through Inhibition of Tumor Angiogenesis
Authors: Silvia Laura Locatelli, Giuseppa Careddu, Armando Chierchia, Srikant Viswanadha, Swaroop Vakkalanka, Luca Castagna, Armando Santoro, Carmelo Carlo-Stella
Journal: Blood (2015)
Eµ-TCL1mTerc -/- Mouse Model for Telomere Dysfunction in Chronic Lymphocytic Leukemia
Authors: Annika Scheffold, Billy Michael Chelliah Jebaraj, André Lechel, Sarah-Fee Katz, Daniela Steinbrecher, Vanni Torresi, Christof Schneider, Daniel Mertens, Hartmut Döhner, Karl-Lenhard Rudolph, Stephan Stilgenbauer
Journal: Blood (2015)
Alternatives in the Evaluation of Suspected Coronary Heart Disease
Authors: Juerg Schwitter
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Relevance of an Extended Diagnostic Work-Out in Patients with Primary Autoimmune Amolytic Anemia (AIHA)
Authors: Francesca R Mauro, Daniele Armiento, Serelina Coluzzi, Maria S De Propris, Francesca Paoloni, Gianluca Giovannetti, Matteo Molica, Luisa Quattrocchi, Michelina Santopietro, Chiara Spadafora, Lucia Granati, Mara Riminucci, Anna Guarini, Gabriella Girelli, Robin Foà
Journal: Blood (2012)
Myeloablative Haploidentical Bone Marrow Transplantation with T Cell Replete Grafts and Post-Transplant Cyclophosphamide: Results of a Phase II Clinical Trial,
Authors: Heather J. Symons, Allen R. Chen, Leo Luznik, Yvette L. Kasamon, Javier Bolanos Meade, Richard J. Jones, Ephraim J. Fuchs
Journal: Blood (2011)
Phospho-Specific Flow Cytometry of Fixed Whole Blood During AML Clinical Trials to Monitor In Vivo FLT3 Inhibition in Leukemic Blasts,
Authors: Alexander E Perl, Grace R Jeschke, Takashi Sato, Shiro Akinaga, Niranjan S. Rao, Maria R. Baer, Mark J. Levis, Martin Carroll
Journal: Blood (2011)
TARGET trial: Molecular profiling of circulating tumour DNA to stratify patients to early phase clinical trials.
Authors: Matthew Krebs, Caroline Dive, Emma Jane Dean, Dominic G Rothwell, John Brognard, Andrew Wallace, Crispin Miller, Natalie Cook, Saeed Rafii, Mahmood Ayub, Hui-Sun Leong, Carla Siswick, Phil Chapman, Nigel Smith, Allan Jordan, Andrew M. Hughes, Richard Marais, Ged Brady
Journal: Journal of Clinical Oncology (2016)

TPS11614 Background: Molecular stratification of patients to early phase trials of targeted therapies is a rational approach to drug development to help maximise benefit for individuals and provide an early indication of drug efficacy. Tumour characterisation is often performed on archival biopsies which may not reflect the current and complete genetic profile of disease and there may be practical issues and delays with obtaining archival specimens. Analysis of circulating tumour DNA (ctDNA) will provide a rapid and contemporaneous profile, perhaps representing tumour heterogeneity and thus a more complete molecular profile than a single biopsy can achieve. The Tumour chARacterisation to Guide Experimental Targeted Therapy Trial (TARGET) will test the hypothesis that ctDNA molecular profiling can be used to help guide selection of experimental medicines and monitor tumour response for patients that receive a matched targeted therapy. Methods: This is a single centre prospective study at the Manchester Cancer Research Centre. Eligible patients referred for consideration of phase 1 trials will be consented for blood sampling, archival tumour analysis and optional fresh biopsies. Circulating free DNA will be extracted from plasma using standard Qiagen protocols and subjected to enrichment for a 654 gene panel followed by next generation sequencing on an Illumina platform. In Part A of the trial, 100 patients will undergo ctDNA analysis for optimisation and reporting of results within 28 days to the Molecular Tumour Board. Data will be considered alongside sequencing of tumour to assess confidence in utilising ctDNA for decision making. In part B results will be required within 14 days for real-time clinical trial selection for up to 250 patients. Serial samples for ctDNA will be collected for patients matched with targeted therapies. Outcomes will include number of patients for which ctDNA analysis guided trial selection and response rates/PFS to matched targeted drugs. Patient derived xenografts will be created to explore drug sensitivity and resistance mechanisms in cases of ctDNA molecular aberrations of uncertain clinical significance. Recruitment commenced in April 2015 and will accrue over 3.5 years.
Personalized Medicine Test of Multi-Drug Protocols Ex Vivo for Hematological Malignancies.
Authors: Teresa A Bennett, Sandra Sapia, Daniel Primo, Lilia Suarez, Santiago Lago, Maria Matoses, Ana Espinosa, Consuelo Tudela, Elena Arroyo, Julian Gorrochategui, William C Jackson, Alex Okun, Horacio Hector Lopez, Isolde Gornemann, Soledad Gallego Melcon, Cristina Diaz de Heredia, Jose Luis Dapena, Josep M Roma, Regina Garcia Delgado, Mari Paz Queipodellano, Alicia Bailen, Manuel Barrios, Eva Diez, Santiago Del Castillo, Ana Isabel Heiniger, Jose Sanchez de Toledo, Manuel Ramirez, Macarena Ortiz, Marcos Gonzáalez, Jesús F. San-Miguel, Enrique M Ocio, Andrew G. Bosanquet, Alberto Orfao, Joan Ballesteros
Journal: Blood (2009)
Leukemia Associated TP53 Mutations in AML Patients ARE Strongly Associated with Complex Karyotype and Poor Outcome
Authors: Anna Ferrari, Cristina Papayannidis, Carmen Baldazzi, Ilaria Iacobucci, Stefania Paolini, Antonella Padella, Viviana Guadagnuolo, Margherita Perricone, Valentina Robustelli, Claudia Venturi, Maria Chiara Abbenante, Sarah Parisi, Chiara Sartor, Francesca Volpato, Nicoletta Testoni, Giorgia Simonetti, Emanuela Ottaviani, Giovanni Martinelli
Journal: Blood (2014)
ETV6 Aberrations Are a Recurrent Event in Pediatric Acute Myeloid Leukemia with Poor Clinical Outcome
Authors: Jasmijn de Rooij, Eva Beuling, Maarten Fornerod, Askar Obulkasim, André Baruchel, Jan Trka, Dirk Reinhardt, Edwin Sonneveld, Martin Zimmermann, Rob Pieters, Marry van den Heuvel-Eibrink, C. Michel Zwaan
Journal: Blood (2014)
High Resolution Genomic Profiling Using Single Nucleotide Polymorphism Microarrays Identifies Multiple Novel Genomic Minimally Deleted Regions in Multiple Myeloma
Authors: Brian A WalKer, Paola E Leone, Nicholas J Dickens, Matthew W Jenner, Laura Chiecchio, GianPaolo Dagrada, Fiona M Ross, Faith E Davies, Gareth J Morgan
Journal: Blood (2008)
Acute Myelogenous Leukemia (AML) Mesenchymal Stromal Cell (MSC) Have Distinct Protein Expression Patterns Compared to Normal MSC
Authors: Steven M. Kornblau, Peter Ruvolo, Rui-Yu Wang, Vivian Ruvolo, Yihua Qiu, Venkata Lokesh Battula, Zhihong Zeng, Teresa McQueen, Suk-Young Yoo, Marina Konopleva, Michael Andreeff
Journal: Blood (2015)
Venous Thromboembolism (VTE) Recurrence in Patients with Recurrent/Metastatic Solid Cancer Receiving Anticoagulation Therapy After Index VTE; Findings From Korean VTE Registry,
Authors: Ho-Young Yhim, Moon Ju Jang, Won-Il Choi, Jeong-Ok Lee, Keun-Wook Lee, Sung Hyun Kim, Yeo-Kyeoung Kim, Hye Jung Chang, Jae-Yong Kwak, Doyeun Oh
Journal: Blood (2011)
First-degree relatives of C282Y homozygous probands with clinically detected hemochromatosis have increased morbidity compared to the general population. The hemochromatosis family study (HEFAS)
Authors: E. M. G. Jacobs, J. C. M. Hendriks, J. J. M. Marx, C. Th. B. M. van Deursen, H. G. Kreettenberg, R. A. de Vries, A. F. H. Stalenhoef, A. L. M. Verbeek, D. W. Swinkels
Journal: American Journal of Hematology (2007)
Comparative Assessment of Significant Psychological Distress In Patients with Malignant and Non-Malignant Hematologic Disorders
Authors: Craig E. Cole, Vicki L McHugh, Michelle A Mathiason, Jonean E Schroeder, Wayne A. Bottner, John P. Farnen, Robert Ettinger, Antoinette Peters, Janette Dawson, Kaye L Johnston
Journal: Blood (2010)
Feasibility of Second Autologous Peripheral Blood Stem Cell (PBSC) Collection Followed by a Second Cycle of High Dose Melphalan (HDM) in Patients Relapsing after an Initial Course of HDM for the Treatment of AL Amyloidosis.
Authors: Karen Quillen, Daniel G. Wright, David C. Seldin, Martha Skinner, Karim Malek, Kathleen T. Finn, Vaishali Sanchorawala
Journal: Blood (2004)
Bidirectional Notch Signaling Between Multiple Myeloma (MM) Cells and Osteocytes As a Potential Target to Inhibit Tumor Growth and Osteoclast Recruitment in MM
Authors: Jesus Delgado-Calle, Judith Anderson, Meloney D. Cregor, Nadia Carlesso, Khalid S. Mohammad, Lilian I. Plotkin, Teresita M. Bellido, G. David Roodman
Journal: Blood (2015)
Erratum for the Research Article: “A Common Mutation in the Defensin DEFB126 Causes Impaired Sperm Function and Subfertility” by T. L. Tollner, S. A. Venners, E. J. Hollox, A. I. Yudin, X. Liu, G. Tang, H. Xing, R. J. Kays, T. Lau, J. W. Overstreet, X. Xu, C. L. Bevins, G. N. Cherr
Journal: Science Translational Medicine (2014)
Catumaxomab therapy in peritoneal carcinomatosis from colon cancer: Clinical benefit in comparison to systemic chemotherapy alone and cytoreductive surgery/hyperthermic chemoperfusion.
Authors: M. A. Ströhlein, M. M. Heiss
Journal: Journal of Clinical Oncology (2011)

488 Background: There is still no effective treatment for the majority of patients suffering from peritoneal carcinomatosis (PC) of colon cancer. Palliative chemotherapy (CHEM) had limited efficacy. Cytoreductive surgery and hyperthermic chemoperfusion (HIPEC) showed promising results, but was manageable in early stage PC patients only. Catumaxomab therapy (CATU) offers a new option for intraperitoneal treatment in all stages of PC. Aim of the study was to evaluate CATU therapy in comparison to HIPEC and systemic therapy. Methods: Between 2005 and 2008, 76 patients suffering from PC of colon cancer were included and treated with systemic chemotherapy alone (35), HIPEC +/- systemic chemotherapy (21) and CATU +/- chemotherapy (22). All patients were assessed for therapy-related severe side effects, incidence of intestinal obstruction-ileus and ascites and for overall survival. Results: Grade IV side effects were observed in 9.1% of CATU patients, 14.3% after HIPEC and 5.7% after CHEM. Ascites was found in not a single patient after CATU vs. one patient after HIPEC (4.5%) and 7 patients after chemotherapy (20%, p&lt;0.03). Intestinal obstruction was found in 22.7% of patients after CATU vs. 14.3% after HIPEC and in 42.9% of patients after chemotherapy (p&lt;0.04). In comparison to systemic chemotherapy, overall survival was significantly increased after CATU (15.2 months, p=0.03) and HIPEC (20.1 months, p=0.02; median follow-up 17 months). Conclusions: Catumaxomab therapy of patients with PC from colon cancer was associated with a preventive effect for accumulation of malignant ascites and intestinal obstruction. Patients receiving CATU or HIPEC therapy concepts showed a survival benefit compared to systemic chemotherapy alone. Therapy strategies containing intraperitoneal catumaxomab treatment may be beneficial in patients with PC from colon cancer, even in advanced PC disease, when HIPEC was not feasible. [Table: see text]
A Knockout Screen of ApiAP2 Genes Reveals Networks of Interacting Transcriptional Regulators Controlling the Plasmodium Life Cycle
Authors: Katarzyna Modrzynska, Claudia Pfander, Lia Chappell, Lu Yu, Catherine Suarez, Kirsten Dundas, Ana Rita Gomes, David Goulding, Julian C. Rayner, Jyoti Choudhary, Oliver Billker
Journal: Cell Host & Microbe (2017)

A family of apicomplexa-specific proteins containing AP2 DNA-binding domains (ApiAP2s) was identified in malaria parasites. This family includes sequence-specific transcription factors that are key regulators of development. However, functions for the majority of ApiAP2 genes remain unknown. Here, a systematic knockout screen in Plasmodium berghei identified ten ApiAP2 genes that were essential for mosquito transmission: four were critical for the formation of infectious ookinetes, and three were required for sporogony. We describe non-essential functions for AP2-O and AP2-SP proteins in blood stages, and identify AP2-G2 as a repressor active in both asexual and sexual stages. Comparative transcriptomics across mutants and developmental stages revealed clusters of co-regulated genes with shared cis promoter elements, whose expression can be controlled positively or negatively by different ApiAP2 factors. We propose that stage-specific interactions between ApiAP2 proteins on partly overlapping sets of target genes generate the complex transcriptional network that controls the Plasmodium life cycle.
Abstract 13903: Application of <i>in vivo</i> Tissue-engineered, Autologous “Biotube” Vascular Grafts, Prepared Using a Less Invasive Device, for Hemodialysis Access in a Canine Model
Authors: Maya Furukoshi, Yasuhide Nakayama
Journal: Circulation (2015)

Purpose: When arteriovenous (AV) fistula is not feasible for vascular access in most patients on hemodialysis, the second choice is interposition AV fistula using synthetic graft. However, the grafts pose risks such as infection and low patency. Therefore, we created in vivo tissue-engineered “Biotube” vascular grafts formed with autologous tissue, based on the tissue encapsulation phenomenon. Previously, we confirmed that vascular-like structure was reconstructed in implanted Biotubes with year-ordered patency in vivo. In this study, we evaluated whether Biotubes could replace vascular access grafts for hemodialysis in the cervical vessels of beagles. Methods and Results: The mold for Biotube preparation was assembled by inserting a silicone rod (external diameter 4 mm; length 50 mm) into an acrylate tubular cover (internal diameter 6 mm; length 50 mm with several longitudinal slits). The molds were embedded into the dorsal subcutaneous pouches of beagles (n=3) for 4 weeks, after which they were harvested by a minimally invasive technique from the same incision (width ca. 20 mm). After removing the molds, Biotubes formed by tissue migration to a silicone surface through the mold slits (internal diameter 4 mm; length 45 mm; wall thickness ca. 1 mm) were obtained. Biotubes were then bypassed between the carotid artery (side-to-end anastomosis) and jugular vein (end-to-end anastomosis) of anesthetized beagles. Following placement of Biotubes, continuous thrill was felt by palpation and ultrasound showed turbulent blood flow. After one month, angiography showed no stenosis, elongation, or hemorrhage in any Biotubes. Percutaneous puncturing with a needle, blood removal and resupply from the needle, and astirction within several minutes were feasible. Conclusions: In our beagle model, Biotubes successfully created an AV shunt that maintained steady blood flow, suggesting that Biotubes have potential clinical use in maintaining vascular access for hemodialysis.
HuMax-CD20, a Novel Fully Human Anti-CD20 Monoclonal Antibody: Results of a Phase I/II Trial in Relapsed or Refractory Follicular Non-Hodgkins’s Lymphoma.
Authors: A. Hagenbeek, T. Plesner, P. Johnson, L. Pedersen, J. Walewski, A. Hellmann, B. Link, T. Robak, M. Wojtukiewicz, M. Pfreundschuh, M. Kneba, A. Engert, P. Sonneveld, J. Petersen, J. Radford
Journal: Blood (2005)
Important Prognostic Impact of Early Monocytes Recovery after Reduced Intensity Conditioning Double Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Adults
Authors: Amandine Le Bourgeois, Thierry Guillaume, Jacques Delaunay, Pierre Peterlin, Viviane Dubruille, Beatrice Mahe, Nicolas Blin, Thomas Gastinne, Maud Voldoire, Alix Duquesne, Steven Le Gouill, Philippe Moreau, Mohamad Mohty, Loic Campion, Patrice Chevallier
Journal: Blood (2014)
Clonal Heterogeneity in Patients with Myelodysplastic Syndromes (MDS) and Complex Karyotypes
Authors: Zuzana Zemanova, Kyra Michalova, Jana Brezinova, Halka Lhotska, Karla Svobodova, Iveta Sarova, Libuse Lizcova, Silvia Izakova, Sarka Ransdorfova, Zdenek Krejcik, Monika Belickova, Magda Siskova, Anna Jonasova, Radana Neuwirtova, Jana Zmolikova, Jaroslav Cermak
Journal: Blood (2014)
Bioluminescent Tracking of Human and Mouse Acute Lymphoblastic Leukemia Reveals Potent Immunogenicity of Luciferase In Some Preclinical Models of Leukemia
Authors: David M Barrett, Alix E Seif, Carmine Carpenito, Eliza P Strong, Carl H. June, Stephan A. Grupp, Gregor S. D. Reid
Journal: Blood (2010)
Club cell secretory protein serum concentration is a surrogate marker of small-airway involvement in asthmatic patients
Authors: Sebastien Bommart, Grégory Marin, Nicolas Molinari, Lucie Knabe, Aurélie Petit, Pascal Chanez, Anne Sophie Gamez, Catherine Devautour, Isabelle Vachier, Arnaud Bourdin
Journal: Journal of Allergy and Clinical Immunology (2017)
Differential Effects of Delta1 and Jagged1 in Early Human Myelopoiesis: Correlation with Distinct Gene-Expression Profiles in CD34+ Cells.
Authors: Hélia Neves, Floor Weerkamp, Brigitta A.E. Naber, Paula Gameiro, Jörg D. Becker, Paulo Lucio, Nuno Clode, Jacques J.M. van Dongen, Frank J.T. Staal, Leonor Parreira
Journal: Blood (2004)
Prognostic Significance of Detection of Minimal Residual Disease by Multiparametric Flow Cytometry Before Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia,
Authors: Fotios P Panitsas, Ioannis Baltathakis, Ioannis Kakkas, Stavros Gigantes, Anna Komitopoulou, Panagiotis Oikonomopoulos, Ifigeneia Tzannou, Eirini Grigoriou, Artemisia Balta, Aliki Vourtsi, Maria Skertsou, John Apostolidis, Aikaterini Psarra, Chryssa Papasteriades, Dimitrios Karakassis, Nikolaos Harhalakis
Journal: Blood (2011)
Expression of Inhibitory Fc Receptor (FcγRIIB) Is a Marker of Poor Response to Rituximab Monotherapy in Follicular Lymphoma (FL).
Authors: Chern Siang Lee, Margaret Ashton-Key, Sergio Cogliatti, Susanne Crowe, Mark S Cragg, Shu-Fang H Schmitz, Michele Ghielmini, Peter Johnson
Journal: Blood (2012)
Integrated Safety From Phase 2 Studies of Monotherapy Carfilzomib in Patients with Relapsed and Refractory Multiple Myeloma (MM): An Updated Analysis
Authors: Seema Singhal, David S. Siegel, Thomas Martin, Ravi Vij, Luhua Wang, Andrzej J Jakubowiak, Sagar Lonial, Vishal Kukreti, Jeffrey A. Zonder, Alvin F. Wong, Leanne McCulloch, Ashraf Z. Badros, Ruben Niesvizky, Robert Z. Orlowski, A. Keith Stewart, Debbi Kotlovker, Sundar Jagannath
Journal: Blood (2011)
Biomarker-Based PET Imaging of Diffuse Intrinsic Pontine Glioma in Mouse Models
Authors: Susanne Kossatz, Brandon Carney, Melanie Schweitzer, Giuseppe Carlucci, Vesselin Z. Miloushev, Uday B. Maachani, Prajwal Rajappa, Kayvan R. Keshari, David Pisapia, Wolfgang A. Weber, Mark M. Souweidane, Thomas Reiner
Journal: Cancer Research (2017)

Abstract Diffuse intrinsic pontine glioma (DIPG) is a childhood brainstem tumor with a universally poor prognosis. Here, we characterize a positron emission tomography (PET) probe for imaging DIPG in vivo. In human histological tissues, the probes target, PARP1, was highly expressed in DIPG compared to normal brain. PET imaging allowed for the sensitive detection of DIPG in a genetically engineered mouse model, and probe uptake correlated to histologically determined tumor infiltration. Imaging with the sister fluorescence agent revealed that uptake was confined to proliferating, PARP1-expressing cells. Comparison with other imaging technologies revealed remarkable accuracy of our biomarker approach. We subsequently demonstrated that serial imaging of DIPG in mouse models enables monitoring of tumor growth, as shown in modeling of tumor progression. Overall, this validated method for quantifying DIPG burden would serve useful in monitoring treatment response in early phase clinical trials. Cancer Res; 77(8); 2112–23. ©2017 AACR.
Probability of Eventual CR After Course 1 of Induction Therapy for Newly-Diagnosed AML As a Function of Speed of Neutrophil and Platelet Recovery
Authors: Laura F Newell, Ravinder K Sandhu, Pamela S Becker, John M. Pagel, Paul C. Hendrie, Roland B. Walter, Stephen H. Petersdorf, Kathleen Shannon Dorcy, Janis L. Abkowitz, Frederick R. Appelbaum, Elihu H. Estey
Journal: Blood (2011)
CCL3 Impairs Osteoblast Function Via Downregulation of Osteocalcin.
Authors: Sonia Vallet, Kishan Patel, Nileshwari Vaghela, Mariateresa Fulciniti, Petter Veiby, Teru Hideshima, Samantha Pozzi, Loredana Santo, Siddhartha Mukherjee, Diana Cirstea, David T Scadden, Kenneth C. Anderson, Noopur Raje
Journal: Blood (2009)
Long-Term Clinical Follow-Up and Safety/Toxicity Analysis in 3 X-CGD Patients Treated by Gene Therapy and Non-Myeloablative Conditioning.
Authors: Marion G. Ott, Manfred Schmidt, Stefan Stein, Kerstin Schwarzwaelder, Ulrich Siler, Ulrike Koehl, Klaus Kuehlcke, Andrea Schilz, Christoph v. Kalle, Dieter Hoelzer, Reinhard Seger, Manuel Grez
Journal: Blood (2006)